生物制剂在大疱性类天疱疮治疗中的应用

doi:10.35541/cjd.20201200

Abstract

Abstract: 【Abstract】 In recent years, new therapeutic targets for bullous pemphigoid (BP) have continued to emerge, and new biologic agents targeting pathogenic antibodies, complements, T helper type 2 (Th2) and Th17 cytokines in BP have also successively entered clinical trials, e.g., the CD20-targeting antibody rituximab and the IgE-targeting antibody omalizumab have been applied in clinical practice and have benefited some patients with refractory BP. This review summarizes the literature and clinical trials related to biologic agents as the treatment strategy for BP, analyzes and discusses clinical application of new biological agents in BP, in order to provide new ideas for the treatment of refractory BP.

Key words: Pemphigoid, bullous, Biologic agent, Treatment, Clinical trial, Rituximab, Omalizumab

Zhou Tong, Geng Songmei. Application of biologic agents in the treatment of bullous pemphigoid[J]. Chinese Journal of Dermatology, 2023, 56(8): 789-793.doi:10.35541/cjd.20201200

References ［56］

［1］	Heymann WR. Bullous pemphigoid: rituximab to the rescue?［J］. J Am Acad Dermatol, 2020,82（5）:1089⁃1090. doi: 10.1016/j.jaad.2020.02.058.
［2］	Hébert V, Bastos S, Drenovska K, et al. International multicentre observational study to assess the efficacy and safety of a 0.5 mg/kg/day starting dose of oral corticosteroids to treat bullous pemphigoid［J］. Br J Dermatol, 2021,185（6）:1232⁃1239. doi: 10.1111/bjd.20593.
［3］	Lonowski S, Sachsman S, Patel N, et al. Increasing evidence for omalizumab in the treatment of bullous pemphigoid［J］. JAAD Case Rep, 2020,6（3）:228⁃233. doi: 10.1016/j.jdcr.2020.01.002.
［4］	Tie D, Da X, Natsuga K, et al. Bullous pemphigoid IgG induces cell dysfunction and enhances the motility of epidermal keratinocytes via rac1/proteasome activation［J］. Front Immunol, 2019,10:200. doi: 10.3389/fimmu.2019.00200.
［5］	Freire PC, Muñoz CH, Stingl G. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants［J］. Br J Dermatol, 2017,177（6）:1644⁃1653. doi: 10.1111/bjd.15924.
［6］	Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid⁃sparing effect［J］. Br J Dermatol, 2020,182（5）:1111⁃1119. doi: 10.1111/bjd.18482.
［7］	Szabolcs P, Reese M, Yancey KB, et al. Combination treatment of bullous pemphigoid with anti⁃CD20 and anti⁃CD25 antibodies in a patient with chronic graft⁃versus⁃host disease［J］. Bone Marrow Transplant, 2002,30（5）:327⁃329. doi: 10.1038/sj.bmt. 1703654.
［8］	Cho YT, Chu CY, Wang LF. First⁃line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate⁃to⁃severe bullous pemphigoid［J］. Br J Dermatol, 2015,173（1）:302⁃304. doi: 10.1111/bjd.13633.
［9］	Tovanabutra N, Payne AS. Clinical outcome and safety of rituximab therapy for pemphigoid diseases［J］. J Am Acad Dermatol, 2020,82（5）:1237⁃1239. doi: 10.1016/j.jaad.2019.11. 023.
［10］	Chee R, Nagendran V, Bansal A, et al. B⁃cell targeted therapy alone may not be effective in bullous pemphigoid［J］. Clin Exp Dermatol, 2007,32（1）:111⁃112. doi: 10.1111/j.1365⁃2230.2006. 02267.x.
［11］	Hall RP 3rd, Streilein RD, Hannah DL, et al. Association of serum B⁃cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients［J］. J Invest Dermatol, 2013,133（12）:2786⁃2788. doi: 10.1038/jid.2013.236.
［12］	Polansky M, Eisenstadt R, DeGrazia T, et al. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients［J］. J Am Acad Dermatol, 2019,81（1）:179⁃186. doi: 10.1016/j.jaad.2019.03.049.
［13］	Watson N, Carrozzo M, Hampton P. A retrospective cohort study reporting rituximab treatment for 33 patients with immunobullous disease［J］. J Oral Pathol Med, 2021,50（1）:92⁃97. doi: 10.1111/jop.13123.
［14］	Schmidt E, Seitz CS, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects［J］. Br J Dermatol, 2007,156（2）:352⁃356. doi: 10.1111/j.1365⁃2133.2006. 07646.x.
［15］	Adler BL, Crew AB, Woodley DT. Early⁃onset neutropenia after rituximab therapy for bullous pemphigoid［J］. Clin Exp Dermatol, 2019,44（3）:334⁃336. doi: 10.1111/ced.13726.
［16］	Schmidt E, Hunzelmann N, Zillikens D, et al. Rituximab in refractory autoimmune bullous diseases［J］. Clin Exp Dermatol, 2006,31（4）:503⁃508. doi: 10.1111/j.1365⁃2230.2006.02151.x.
［17］	Maglie R, Antiga E, Quintarelli L, et al. Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab［J］. Eur J Dermatol, 2019,29（2）:213⁃215. doi: 10.1684/ejd.2019.3499.
［18］	Ahmed AR, Shetty S, Kaveri S, et al. Treatment of recalcitrant bullous pemphigoid （BP） with a novel protocol: a retrospective study with a 6⁃year follow⁃up［J］. J Am Acad Dermatol, 2016,74（4）:700⁃708.e3. doi: 10.1016/j.jaad.2015.11.030.
［19］	Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real⁃life clinical practice［J］. Drug Des Devel Ther, 2019,13:3181⁃3186. doi: 10.2147/DDDT.S214307.
［20］	Seyed Jafari SM, Gadaldi K, Feldmeyer L, et al. Effects of omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid［J］. Front Immunol, 2019,10:1919. doi: 10.3389/fimmu.2019.01919.
［21］	Fairley JA, Baum CL, Brandt DS, et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab［J］. J Allergy Clin Immunol, 2009,123（3）:704⁃705. doi: 10.1016/j.jaci.2008.11.035.
［22］	Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous pemphigoid［J］. J Am Acad Dermatol, 2014,71（3）:468⁃474. doi: 10.1016/j.jaad.2014.04.053.
［23］	James T, Salman S, Stevenson B, et al. IgE blockade in autoimmunity: omalizumab induced remission of bullous pemphigoid［J］. Clin Immunol, 2019,198:54⁃56. doi: 10.1016/j.clim.2018.12.015.
［24］	Vico⁃Alonso C, Calleja⁃Algarra A, Aragón⁃Miguel R, et al. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: a case report［J］. Dermatol Ther, 2019,32（2）:e12829. doi: 10.1111/dth.12829.
［25］	Menzinger S, Kaya G, Schmidt E, et al. Biological and clinical response to omalizumab in a patient with bullous pemphigoid［J］. Acta Derm Venereol, 2018,98（2）:284⁃286. doi: 10.2340/00015555⁃2845.
［26］	Balakirski G, Alkhateeb A, Merk HF, et al. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid⁃sparing agent: report of two cases and review of literature［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1778⁃1782. doi: 10.1111/jdv. 13758.
［27］	London VA, Kim GH, Fairley JA, et al. Successful treatment of bullous pemphigoid with omalizumab［J］. Arch Dermatol, 2012,148（11）:1241⁃1243. doi: 10.1001/archdermatol.2012.1604.
［28］	Navarro⁃Triviño FJ, Llamas⁃Molina JM, Ayen⁃Rodriguez A, et al. Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient［J］. Eur J Hosp Pharm, 2021,28（6）:350⁃352. doi: 10.1136/ejhpharm⁃2020⁃002418.
［29］	Sinha S, Agrawal D, Sardana K, et al. Complete remission in a patient with treatment refractory bullous pemphigoid after a single dose of omalizumab［J］. Indian Dermatol Online J, 2020,11（4）:607⁃611. doi: 10.4103/idoj.IDOJ_438_19.
［30］	Garrido PM, Alexandre MI, Travassos AR, et al. Dipeptidyl⁃peptidase IV inhibitor⁃associated bullous pemphigoid efficiently treated with omalizumab［J］. Dermatol Ther, 2020,33（6）:e14160. doi: 10.1111/dth.14160.
［31］	De D, Kaushik A, Handa S, et al. Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co⁃morbidities［J］. J Eur Acad Dermatol Venereol, 2021,35（7）:e469⁃e472. doi: 10.1111/jdv.17229.
［32］	Neumark M, Tal Y, Zlotogorski A, et al. Effective treatment for bullous pemphigoid with omalizumab［J］. Harefuah, 2020,159（1）:29⁃30.
［33］	Ewy S, Pham H, Quan K, et al. Successful omalizumab therapy for bullous pemphigoid despite transient reaction［J］. J Drugs Dermatol, 2019,18（9）:947⁃949.
［34］	Gönül MZ, Keseroglu HO, Ergin C, et al. Bullous pemphigoid successfully treated with omalizumab［J］. Indian J Dermatol Venereol Leprol, 2016,82（5）:577⁃579. doi: 10.4103/0378⁃6323. 183628.
［35］	Bilgiç Temel A, Bassorgun CI, Akman⁃Karakaş A, et al. Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments［J］. Case Rep Dermatol, 2017,9（1）:38⁃44. doi: 10. 1159/000452828.
［36］	Adachi M, Kozawa M, Yoshisue H, et al. Real⁃world safety and efficacy of omalizumab in patients with severe allergic asthma: a long⁃term post⁃marketing study in Japan［J］. Respir Med, 2018,141:56⁃63. doi: 10.1016/j.rmed.2018.06.021.
［37］	Lapeere H, Baeck M, Stockman A, et al. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real⁃world study in Belgium［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:127⁃134. doi: 10.1111/jdv. 15684.
［38］	邱于芳, 钟珊, 王佩茹, 等. 利妥昔单抗联合糖皮质激素治疗难治性大疱性皮肤病临床分析［J］. 临床皮肤科杂志, 2011,40（9）:536⁃539. doi: 10.3969/j.issn.1000⁃4963.2011.09.008.
［39］	敖俊红. 奥马珠单抗成功治疗大疱性类天疱疮［J］. 实用皮肤病学杂志, 2013,6（01）:63.
［40］	Russo R, Cozzani E, Gasparini G, et al. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases?［J］. Dermatol Ther, 2020,33（1）:e13190. doi: 10.1111/dth.13190.
［41］	Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus［J］. Dermatol Online J, 2019,25（11）:13030/qt25q9w6r9.
［42］	Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria［J］. J Allergy Clin Immunol Pract, 2019,7（5）:1659⁃1661.e1. doi: 10.1016/j.jaip.2018.11.018.
［43］	Seyed Jafari SM, Feldmeyer L, Bossart S, et al. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid［J］. Front Immunol, 2020,11:611549. doi: 10.3389/fimmu.2020.611549.
［44］	Suzuki M, Yamaguchi Y, Nakamura K, et al. Serum thymus and activation⁃regulated chemokine （TARC/CCL17） may be useful to predict the disease activity in patients with bullous pemphigoid［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:e121⁃e124. doi: 10.1111/jdv.16851.
［45］	Kowalski EH, Kneibner D, Kridin K, et al. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid［J］. Autoimmun Rev, 2019,18（5）:526⁃534. doi: 10.1016/j.autrev.2019.03.009.
［46］	Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the treatment of recalcitrant bullous pemphigoid［J］. JAMA Dermatol, 2018,154（10）:1225⁃1226. doi: 10.1001/jamadermatol.2018.2526.
［47］	Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series［J］. J Am Acad Dermatol, 2020,83（1）:46⁃52. doi: 10.1016/j.jaad.2020.01.089.
［48］	Valdebran M, Kowalski EH, Kneiber D, et al. Epidermal expression of eotaxins and thymic stromal lymphopoietin in eosinophil rich dermatoses［J］. Arch Dermatol Res, 2019,311（9）:705⁃710. doi: 10.1007/s00403⁃019⁃01954⁃5.
［49］	Kushner CJ, Payne AS. Increasing the complement of therapeutic options in bullous pemphigoid［J］. J Invest Dermatol, 2018,138（2）:246⁃248. doi: 10.1016/j.jid.2017.09.026.
［50］	Freire PC, Muñoz CH, Derhaschnig U, et al. Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal⁃epidermal junction in bullous pemphigoid［J］. J Invest Dermatol, 2019,139（12）:2417⁃2424.e2. doi: 10.1016/j.jid.2019.04.025.
［51］	Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2020,383（14）:1389⁃1391. doi: 10.1056/NEJMc2016395.
［52］	Giusti D, Bini E, Terryn C, et al. NET Formation in bullous pemphigoid patients with relapse is modulated by IL⁃17 and IL⁃23 interplay［J］. Front Immunol, 2019,10:701. doi: 10.3389/fimmu.2019.00701.
［53］	Tukaj S, Kleszczyński K, Vafia K, et al. Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid［J/OL］. PLoS One, 2013,8（7）:e70496［2020⁃11⁃11］. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728143/. doi: 10.1371/journal.pone.0070496.
［54］	Margaroli C, Bradley B, Thompson C, et al. Distinct compartmentalization of immune cells and mediators characterizes bullous pemphigoid disease［J］. Exp Dermatol, 2020,29（12）:1191⁃1198. doi: 10.1111/exd.14209.
［55］	Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid［J］. J Am Acad Dermatol, 2020,83（1）:53⁃62. doi: 10.1016/j.jaad.2019.07.060.
［56］	Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus［J］. N Engl J Med, 2020,383（2）:141⁃150. doi: 10.1056/NEJMoa1917006.

[1]	Yuan-xiang LIU yuan liang 欣荣赵 Ma Lin. Janus kinase inhibitors for the treatment of five children with severe alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 849-852.
[2]	Zhong Jiemin, Shao Lei, Liang Yimin, Huang Qiongxiao, Xia Manqi, Liu Yumei. Comparative study on efficacy and safety of single microneedle radiofrequency versus photodynamic therapy in the treatment of inflammatory lesions of moderate to severe facial acne vulgaris [J]. Chinese Journal of Dermatology, 2023, 56(8): 751-755.
[3]	Wang Junxia, Guo Weinan, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Efficacy of autologous fat grafting in the treatment of 40 cases of stable linear scleroderma: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(8): 762-765.
[4]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[5]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[6]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[7]	Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517.
[8]	Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530.
[9]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[10]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[11]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[12]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[13]	Guo Weinan, Wang Junxia, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Clinical efficacy of autologous adipose-derived stem cell gel grafting in the treatment of depressed acne scars [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210867-e20210867.
[14]	Wang Xingwang, Yang Huilan. Reasonable selection of antiviral agents for herpes zoster [J]. Chinese Journal of Dermatology, 2023, 56(3): 262-265.
[15]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.

Application of biologic agents in the treatment of bullous pemphigoid

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［56］

Related Articles 15

Metrics

Comments

Recommended 10